The Promise of Neuroprotective Agents in Parkinson’s Disease

Parkinson’s disease (PD) is characterized by loss of dopamine neurons in the substantia nigra of the brain. Since there are limited treatment options for PD, neuroprotective agents are currently being tested as a means to slow disease progression. Agents targeting oxidative stress, mitochondrial dysfunction, and inflammation are prime candidates for neuroprotection. This review identifies Rasagiline, Minocycline, and creatine, as the most promising neuroprotective agents for PD, and they are all currently in phase III trials. Other agents possessing protective characteristics in delaying PD include stimulants, vitamins, supplements, and other drugs. Additionally, combination therapies also show benefits in slowing PD progression. The identification of neuroprotective agents for PD provides us with therapeutic opportunities for modifying the course of disease progression and, perhaps, reducing the risk of onset when preclinical biomarkers become available.

[1]  M. Roghani,et al.  Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence 1 1 Published on the World Wide Web 3 January 2001. , 2001, Brain Research.

[2]  E. Esposito,et al.  Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study , 2006, Brain Research.

[3]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[4]  D. Maraganore,et al.  Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study , 2006, Neurology.

[5]  D. Patel,et al.  Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse , 2008, Brain Research.

[6]  R. Reiter,et al.  Melatonin in Relation to Cellular Antioxidative Defense Mechanisms , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  D. Casper,et al.  Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro , 2000, Neuroscience Letters.

[8]  N. Volkow,et al.  Inhibition of monoamine oxidase B in the brains of smokers , 1996, Nature.

[9]  H Checkoway,et al.  Dietary factors in Parkinson's disease: The role of food groups and specific foods , 1999, Movement disorders : official journal of the Movement Disorder Society.

[10]  Xin Wang,et al.  Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures , 2003, Neuroreport.

[11]  K. Okamoto,et al.  Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease , 2004, Journal of the Neurological Sciences.

[12]  D. Casper,et al.  Dopaminergic neurotoxicity by 6‐OHDA and MPP+: Differential requirement for neuronal cyclooxygenase activity , 2005, Journal of neuroscience research.

[13]  M. Weisskopf,et al.  Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. , 2010, Parkinsonism & related disorders.

[14]  C G Coimbra,et al.  High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. , 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[15]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3, an inducer of glial cell line‐derived neurotrophic factor , 1996, Neuroreport.

[16]  J. Benito-León,et al.  Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease , 2005, Journal of Neural Transmission.

[17]  H. Arai,et al.  Vitamin E and transfer proteins , 2003, Current opinion in lipidology.

[18]  Y. Akao,et al.  An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells , 2002, Neuroscience Letters.

[19]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[20]  M. Youdim,et al.  Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate] , 2001, Cellular and Molecular Neurobiology.

[21]  Glenna A Dowling,et al.  Melatonin for sleep disturbances in Parkinson's disease. , 2005, Sleep medicine.

[22]  C. Marsden,et al.  α‐tocopherol levels in brain are not altered in Parkinson's disease , 1992 .

[23]  S. Daya,et al.  Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation. , 2006, Life sciences.

[24]  F. Gomez-Pinilla,et al.  Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. , 2004, Journal of neurotrauma.

[25]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[26]  N. Greig,et al.  A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. , 2002, The Journal of pharmacology and experimental therapeutics.

[27]  M. Catalán,et al.  Serum levels of β-carotene and other carotenoids in Parkinson's disease , 1993, Neuroscience Letters.

[28]  S. Arneric,et al.  Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[29]  T. Perlmann,et al.  Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. , 2000, Science.

[30]  Victor Tapias,et al.  Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model , 2010, Journal of neuroscience research.

[31]  Christian Hölscher,et al.  The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[32]  N. Morioka,et al.  Nonsteroidal Anti-Inflammatory Drugs Potentiate 1-Methyl-4-phenylpyridinium (MPP+)-Induced Cell Death by Promoting the Intracellular Accumulation of MPP+ in PC12 Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  S. Kügler,et al.  Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons , 2010, Acta Neuropathologica.

[34]  M. Beal,et al.  Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects , 1997, Annals of neurology.

[35]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[36]  K. Marder,et al.  Altered systemic iron metabolism in Parkinson's disease , 1997, Neurology.

[37]  F. Cicchetti,et al.  Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  M. Traber,et al.  Vitamin E in humans: demand and delivery. , 1996, Annual review of nutrition.

[39]  D. Prou,et al.  Toxin-induced models of Parkinson’s disease , 2005, NeuroRX.

[40]  W. Tatton,et al.  Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B , 2003, Journal of Neural Transmission.

[41]  W. Oertel,et al.  Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  E. Frieden,et al.  NADH-FMN oxidoreductase activity and iron content of organs from riboflavin and iron-deficient rats. , 1977, The Journal of nutrition.

[43]  R. Demir,et al.  The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson’s disease , 2011, Neurochemistry International.

[44]  V. Zissimopoulos,et al.  Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration , 2009, Clinical Neurology and Neurosurgery.

[45]  R. Clavier,et al.  Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse , 1985, Neuroscience Letters.

[46]  A. Kupsch,et al.  Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine , 1997, Experimental Brain Research.

[47]  G. Escames,et al.  Comparative effects of melatonin, l‐deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro , 2000, Journal of pineal research.

[48]  H. Baik,et al.  Melatonin protects 6‐OHDA‐induced neuronal death of nigrostriatal dopaminergic system , 1998, Neuroreport.

[49]  F. Cicchetti,et al.  Impact of omega-3 fatty acids in Parkinson's disease , 2011, Ageing Research Reviews.

[50]  A. Kingsbury,et al.  Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease , 2008, Journal of Neuroinflammation.

[51]  S. Papapetropoulos.  A Double-Blind, Delayed-Start Trial of Rasagiline In Parkinson's Disease , 2010 .

[52]  M. Beal,et al.  A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease , 1999, BioFactors.

[53]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[54]  W. Rausch,et al.  Minocycline Protects Dopaminergic Neurons Against Long-Term Rotenone Toxicity , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[55]  D. Jump,et al.  Dietary polyunsaturated fatty acids and regulation of gene transcription , 2002, Current opinion in lipidology.

[56]  G. Winterer,et al.  Neuroprotective and neurotoxic effects of nicotine. , 2009, Pharmacopsychiatry.

[57]  M. Beal,et al.  Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity , 2007, NeuroMolecular Medicine.

[58]  M. Beal,et al.  Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity , 1998, Experimental Neurology.

[59]  G. Littarru.  Biomedical and clinical aspects of coenzyme Q , 1993, The clinical investigator.

[60]  K. Nakashima,et al.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells , 2008, Neuroscience Letters.

[61]  T. Slater,et al.  Studies on lipid peroxidation in normal and tumour tissues. The Novikoff rat liver tumour. , 1986, The Biochemical journal.

[62]  George E. Marzloff,et al.  Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally , 2006, Brain Research.

[63]  J. Holst,et al.  Neuroprotective properties of GLP-1: theoretical and practical applications , 2011, Current medical research and opinion.

[64]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[65]  J. Andersen,et al.  Glutathione, iron and Parkinson's disease. , 2002, Biochemical pharmacology.

[66]  J. Glover.  The conversion of beta-carotene into vitamin A. , 1960, Vitamins and hormones.

[67]  J B Schulz,et al.  Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.

[68]  飯田 基之.  Dopamine D'2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist , 1999 .

[69]  A. Kupsch,et al.  Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline , 2001, Journal of Neural Transmission.

[70]  L. Grégoire,et al.  Docosahexaenoic acid reduces levodopa‐induced dyskinesias in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine monkeys , 2006, Annals of neurology.

[71]  B. Marchetti,et al.  Endogenous melatonin protects L‐DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long‐term L‐DOPA therapy in Parkinson's disease , 2006, Journal of pineal research.

[72]  Hyon K. Choi,et al.  Diet, urate, and Parkinson's disease risk in men. , 2008, American journal of epidemiology.

[73]  R. Grünewald.  Ascorbic acid in the brain , 1993, Brain Research Reviews.

[74]  D Spiegelman,et al.  Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk , 2002, Neurology.

[75]  P. Silburn,et al.  Acute nicotine enhances strategy-based semantic processing in Parkinson's disease. , 2011, The international journal of neuropsychopharmacology.

[76]  L. Carr,et al.  Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke , 1990, Neuropharmacology.

[77]  M. Beal,et al.  Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases , 2008, NeuroMolecular Medicine.

[78]  F. Jiménez-Jiménez,et al.  Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease , 1993, Journal of the Neurological Sciences.

[79]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[80]  M. Mattson,et al.  Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo , 1998, Journal of neuroscience research.

[81]  P. Coates,et al.  The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds. , 2004, Free radical biology & medicine.

[82]  K. Takata,et al.  Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models , 2009, Journal of neuroscience research.

[83]  P. Worley,et al.  Cyclooxygenases and the central nervous system. , 1997, Prostaglandins.

[84]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[85]  R. Elble,et al.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease , 2006, Neurology.

[86]  Sehee Kim,et al.  Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. , 2009, The Journal of endocrinology.

[87]  F. Speizer,et al.  Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease , 2003, Neurology.

[88]  W Tatton,et al.  The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo , 2001, Annals of the New York Academy of Sciences.

[89]  F. Herrera,et al.  Protective effect of melatonin in a chronic experimental model of Parkinson’s disease , 2002, Brain Research.

[90]  J. Y. Wang,et al.  Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. , 2001, Brain research.

[91]  T. Obata.  Phytic acid suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum , 2003, Brain Research.

[92]  R. Duvoisin,et al.  Studies on the Oxidation of the Dopaminergic Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,5,6‐Tetrahydropyridine by Monoamine Oxidase B , 1985, Journal of neurochemistry.

[93]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[94]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[95]  Honglei Chen,et al.  Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[96]  M. Cudkowicz,et al.  Coenzyme Q treatment of neurodegenerative diseases of aging. , 2007, Mitochondrion.

[97]  Yoshimi Fujii,et al.  Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. , 2005, The Journal of nutrition.

[98]  François Berger,et al.  New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.

[99]  K. Murros,et al.  Low plasma uric acid level in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[100]  P. Teismann,et al.  Glutathione—a review on its role and significance in Parkinson's disease , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[101]  B. Hoffer,et al.  Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats , 2001, Brain Research.

[102]  R. de Caterina,et al.  The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKCε inhibition , 2006, Proceedings of the National Academy of Sciences.

[103]  A. Pol.  Tyrosine hydroxylase immunoreactive neurons throughout the hypothalamus receive glutamate decarboxylase immunoreactive synapses: a double pre- embedding immunocytochemical study with particulate silver and HRP , 1986 .

[104]  V. Kartha,et al.  Antioxidant function of vitamin A. , 1977, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[105]  L. Golub,et al.  Tetracyclines Inhibit Protein Glycation in Experimental Diabetes , 1998, Advances in dental research.

[106]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[107]  N. Ogawa,et al.  Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist , 1999, Brain Research.

[108]  A. Kupsch,et al.  Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. , 1995, Neuroreport.

[109]  Yoshihiro Sato,et al.  High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease [RETRACTED] , 1997, Neurology.

[110]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[111]  M. Youdim,et al.  The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. , 2003, Biochemical pharmacology.

[112]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[113]  B. Glass,et al.  Melatonin and 6‐hydroxymelatonin protect against iron‐induced neurotoxicity , 2006, Journal of neurochemistry.

[114]  W. Ondo,et al.  Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[115]  R. Sandyk.  Mechanisms of action of ECT in Parkinson's disease: possible role of pineal melatonin. , 1990, The International journal of neuroscience.

[116]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[117]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[118]  J. Sheng,et al.  Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1). , 1987, Life sciences.

[119]  J. Andersen,et al.  Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. , 2006, Free radical biology & medicine.

[120]  K. Jishage,et al.  Delayed-onset ataxia in mice lacking α-tocopherol transfer protein: Model for neuronal degeneration caused by chronic oxidative stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[121]  Hyon K. Choi,et al.  Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. , 2005, Arthritis and rheumatism.

[122]  D. D. Di Monte.  Mitochondrial DNA and Parkinson's disease , 1991, Neurology.

[123]  M. Mattson,et al.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism , 2009, Proceedings of the National Academy of Sciences.

[124]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[125]  S. Heales,et al.  Depletion of glutathione does not affect electron transport chain complex activity in brain mitochondria: Implications for Parkinson disease and postmortem studies. , 2011, Free radical biology & medicine.

[126]  W. H. Church,et al.  Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation , 1994, Brain Research Bulletin.

[127]  Y. Ishibashi,et al.  Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats , 2002, Journal of neurochemistry.

[128]  M. Irizarry,et al.  Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration , 2010, Experimental Neurology.

[129]  M. Youdim,et al.  The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing , 2003, The FASEB Journal.

[130]  E. Bézard,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment , 2004, Neurology.

[131]  R. Wurtman,et al.  Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus , 2007, Brain Research.

[132]  M. Beal,et al.  Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders , 2001, Annals of neurology.

[133]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[134]  Y. Akao,et al.  Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindan , 2002, Journal of neurochemistry.

[135]  H. Powers.  A study of maternofetal iron transfer in the riboflavin-deficient rat. , 1987, Journal of NutriLife.

[136]  E. Tolosa,et al.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways , 2005, Experimental Brain Research.

[137]  I. Schlesinger,et al.  Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[138]  M. Beal,et al.  Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases , 2009, Journal of neurochemistry.

[139]  A. Ascherio,et al.  Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease , 2006, The Journal of Neuroscience.

[140]  J. Borowitz,et al.  Dopamine‐Induced Apoptosis Is Mediated by Oxidative Stress and Is Enhanced by Cyanide in Differentiated PC12 Cells , 2000, Journal of neurochemistry.

[141]  M. Memo,et al.  Various Ca2+ entry blockers prevent glutamate-induced neurotoxicity. , 1991, European journal of pharmacology.

[142]  C. Shults,et al.  Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease , 2003, BioFactors.

[143]  M. Youdim,et al.  Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B , 2001, British journal of pharmacology.

[144]  M. Etminan,et al.  NSAID Use and the Risk of Parkinson’s Disease , 2009, Drugs & aging.

[145]  J. Jankovic,et al.  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease , 2007, Neurology.

[146]  A. Tappel.  Vitamin E as the Biological Lipid Antioxidant , 1962 .

[147]  S. Jick,et al.  NSAID use and risk of Parkinson disease: a population‐based case‐control study , 2011, European journal of neurology.

[148]  M. Reddy,et al.  Phytic Acid Protects against 6-Hydroxydopamine-Induced Dopaminergic Neuron Apoptosis in Normal and Iron Excess Conditions in a Cell Culture Model , 2011, Parkinson's disease.

[149]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[150]  N. Greig,et al.  Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. , 2005, Current Alzheimer research.

[151]  Laurie A Andrews,et al.  Decaffeinated Coffee and Nicotine-Free Tobacco Provide Neuroprotection in Drosophila Models of Parkinson's Disease through an NRF2-Dependent Mechanism , 2010, The Journal of Neuroscience.

[152]  E. Bézard,et al.  Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease , 2004, The European journal of neuroscience.

[153]  K. Davies,et al.  Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. , 1986, The Biochemical journal.

[154]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes , 2011, The Lancet Neurology.

[155]  J. Joseph,et al.  Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. , 1996, Free radical biology & medicine.

[156]  M. M. Esteban,et al.  Melatonin prevents apoptosis induced by 6‐hydroxydopamine in neuronal cells: Implications for Parkinson's disease , 1998, Journal of pineal research.

[157]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[158]  M. Quik.  Smoking, nicotine and Parkinson's disease , 2004, Trends in Neurosciences.

[159]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[160]  J. O'Callaghan,et al.  Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐α , 2006, Journal of neurochemistry.

[161]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[162]  Annette M. Schmid,et al.  Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.

[163]  N. Morioka,et al.  Nonsteroidal Anti-Inflammatory Drugs Potentiate 1-Methyl-4-phenylpyridinium ( MPP )-Induced Cell Death by Promoting the Intracellular Accumulation of MPP in PC 12 Cells , 2004 .

[164]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[165]  M. Beal,et al.  Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism , 2008, Journal of neurochemistry.

[166]  Serum levels of beta-carotene and other carotenoids in Parkinson's disease. , 1993, Neuroscience letters.

[167]  D. Surmeier,et al.  Calcium homeostasis, selective vulnerability and Parkinson's disease , 2009, Trends in Neurosciences.

[168]  F. Chung,et al.  Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. , 1995, Free radical biology & medicine.

[169]  A. N. van den Pol,et al.  Tyrosine hydroxylase immunoreactive neurons throughout the hypothalamus receive glutamate decarboxylase immunoreactive synapses: a double pre- embedding immunocytochemical study with particulate silver and HRP , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[170]  A. Granholm,et al.  Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease , 2006, Brain Research.

[171]  D. Surmeier,et al.  Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[172]  R. Kostrzewa,et al.  Effects of MPTP and vitamin E treatments on immune function in mice. , 1992, International journal of immunopharmacology.

[173]  R. Kostrzewa,et al.  Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. , 1991, Neuroreport.

[174]  Langston Jw.  Epidemiology versus genetics in parkinson's disease: Progress in resolving an age-old debate , 1998 .

[175]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[176]  R. Ashley,et al.  How do Tetracyclines Work? , 1998, Advances in dental research.

[177]  M. Hernán,et al.  A Prospective Study” , 2007 .

[178]  M. Mattson,et al.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.

[179]  G. Nappi,et al.  Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease , 2004, Experimental Neurology.

[180]  P. LeWitt.  Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. , 1994, Journal of neural transmission. Supplementum.

[181]  A. Kupsch,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level , 1996, Brain Research.

[182]  Yi Zhao,et al.  Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese , 2003, Journal of the Neurological Sciences.

[183]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[184]  H. Powers.  Riboflavin (vitamin B-2) and health. , 2003, The American journal of clinical nutrition.

[185]  M. Murer,et al.  Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease , 2001, Progress in Neurobiology.

[186]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[187]  A. Hofman,et al.  Serum uric acid levels and the risk of Parkinson disease , 2005, Annals of neurology.

[188]  D. Morens,et al.  Case‐control study of idiopathic Parkinson's disease and dietary vitamin E intake , 1996, Neurology.

[189]  D. Harrison,et al.  Peroxidase Properties of Extracellular Superoxide Dismutase: Role of Uric Acid in Modulating In Vivo Activity , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[190]  J. Andersen,et al.  Inducible Alterations of Glutathione Levels in Adult Dopaminergic Midbrain Neurons Result in Nigrostriatal Degeneration , 2007, The Journal of Neuroscience.

[191]  A. Hofman,et al.  Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease , 2007, Neuroepidemiology.

[192]  M. Akbar,et al.  Protective effects of docosahexaenoic acid in staurosporine‐induced apoptosis: involvement of phosphatidylinositol‐3 kinase pathway , 2002, Journal of neurochemistry.

[193]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[194]  H. Fukuyama,et al.  Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case–control study in Japan , 2010, British Journal of Nutrition.

[195]  M. Schwarzschild,et al.  Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease , 2010, Neuroscience.

[196]  V. Yong,et al.  Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment , 1986, Neuroscience Letters.

[197]  E. Shohami,et al.  Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. , 1999, European journal of pharmacology.

[198]  M. Schwarzschild,et al.  Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice , 2002, Neuroscience Letters.

[199]  Honglei Chen,et al.  Use of ibuprofen and risk of Parkinson disease , 2011, Neurology.

[200]  Y. Akao,et al.  Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. , 2000, Journal of neural transmission. Supplementum.

[201]  J. A. Mills.  Nonsteroidal Anti-Inflammatory Drugs , 1974 .

[202]  L. Horrocks,et al.  Health benefits of docosahexaenoic acid (DHA) , 1999, Pharmacological research.

[203]  J. Langston,et al.  Epidemiology versus genetics in parkinson's disease: Progress in resolving an age‐old debate , 1998, Annals of neurology.

[204]  R. Munhoz,et al.  Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. , 2008, Journal of affective disorders.

[205]  Kazuyuki Takata,et al.  Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4‐phenylbutyrate, a chemical chaperone , 2007, Journal of neurochemistry.

[206]  F. Jiménez-Jiménez,et al.  Serum levels of alpha‐tocopherol (vitamin E) in Parkinson's disease , 1992, Neurology.

[207]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[208]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[209]  D. Jiang,et al.  Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice , 2005, Journal of Neural Transmission.

[210]  S. Cobb,et al.  SERUM-URIC-ACID LEVELS , 1966 .

[211]  B. Oostra,et al.  DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.

[212]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[213]  C. Junot,et al.  Glutathione revisited: a vital function in iron metabolism and ancillary role in thiol‐redox control , 2011, The EMBO journal.

[214]  K. Ingold,et al.  Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? , 1983, Archives of biochemistry and biophysics.

[215]  L. Klaidman,et al.  MPTP toxicity in the mouse brain and vitamin E , 1990, Neuroscience Letters.

[216]  D. Macêdo,et al.  Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats , 2006, Pharmacology Biochemistry and Behavior.

[217]  Yoshikuni Mizuno,et al.  Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain , 2006, Journal of neurochemistry.

[218]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[219]  S. Shavali,et al.  Neuroprotective actions of coenzyme Q10 in Parkinson's disease. , 2004, Methods in enzymology.

[220]  R. Reiter,et al.  Melatonin and parkinson’s disease , 2005, Endocrine.

[221]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[222]  Wiklund Ra,et al.  First of two parts , 1997 .

[223]  C. Marsden,et al.  Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain , 2005, Journal of Neural Transmission.

[224]  Xuemei Huang,et al.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. , 2009, American journal of epidemiology.

[225]  Y. Agid,et al.  Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism , 2003, Neurology.

[226]  M. Joghataie,et al.  Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. , 2004, Parkinsonism & related disorders.

[227]  D. Bagchi,et al.  Protective ability of acetylsalicylic acid (aspirin) to scavenge radiation induced free radicals in J774A.1 macrophage cells. , 1998, Research Communications in Molecular Pathology and Pharmacology.

[228]  M. Quik,et al.  Nicotinic receptors and Parkinson's disease. , 2000, European journal of pharmacology.

[229]  J. Langston,et al.  Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates , 2006, Journal of neurochemistry.

[230]  V. Yong,et al.  Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1987, Journal of the neurological sciences.

[231]  C. Meshul,et al.  Nicotine Alters Striatal Glutamate Function and Decreases the Apomorphine-Induced Contralateral Rotations in 6-OHDA-Lesioned Rats , 2002, Experimental Neurology.

[232]  Vanesa Martín,et al.  Several antioxidant pathways are involved in astrocyte protection by melatonin , 2002, Journal of pineal research.

[233]  Amany A. Abdin,et al.  Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism , 2008, Neuropharmacology.

[234]  A. Shamsuddin,et al.  IP6: a novel anti-cancer agent. , 1997, Life sciences.

[235]  W. Kukull,et al.  Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[236]  P. Riederer,et al.  Altered redox state of platelet coenzyme Q10 in Parkinson's disease , 2000, Journal of Neural Transmission.

[237]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[238]  A. Mackay-Sim,et al.  Vitamin d3 and brain development , 2003, Neuroscience.

[239]  S. Barger,et al.  Vitamin E suppression of microglial activation is neuroprotective , 2001, Journal of neuroscience research.

[240]  N. Bazan.  Neuroprotectin D1 (NPD1): A DHA‐Derived Mediator that Protects Brain and Retina Against Cell Injury‐Induced Oxidative Stress , 2005, Brain pathology.

[241]  W. Scott,et al.  Vitamin D Receptor Gene as a Candidate Gene for Parkinson Disease , 2011, Annals of human genetics.

[242]  Ali Samii,et al.  Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis , 2005, The Lancet Neurology.

[243]  I. Antolín,et al.  Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage , 1999, Brain Research.

[244]  F. Vaglini,et al.  Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism , 2005, Journal of Neural Transmission.

[245]  Eric Jacobs,et al.  Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.

[246]  E. Pileblad,et al.  Reduction of Brain Glutathione by l‐Buthionine Sulfoximine Potentiates the Dopamine‐Depleting Action of 6‐Hydroxydopamine in Rat Striatum , 1989, Journal of neurochemistry.

[247]  O. Andreassen,et al.  Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.

[248]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[249]  F. M. Huennekens.  Flavin nucleotides and flavoproteins , 1956, Experientia.

[250]  P. Sleiman,et al.  The coenzyme Q10 status of the brain regions of Parkinson’s disease patients , 2008, Neuroscience Letters.

[251]  B. Ritz,et al.  Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease , 2007, Neurology.

[252]  E. Hirsch,et al.  Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+ , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[253]  D. James Surmeier,et al.  ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.

[254]  M. Youdim,et al.  Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[255]  Wenbo Zhou,et al.  Phenylbutyrate Up-regulates the DJ-1 Protein and Protects Neurons in Cell Culture and in Animal Models of Parkinson Disease* , 2011, The Journal of Biological Chemistry.

[256]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[257]  K. Mohanakumar,et al.  Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats , 2003, Brain Research.

[258]  I. Ziv,et al.  Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.

[259]  W. Willett,et al.  Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.

[260]  R. Wurtman,et al.  Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease , 2008, Neuroscience Research.

[261]  James M. Wright,et al.  α-Tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1987, Journal of the Neurological Sciences.

[262]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[263]  M. Ebadi,et al.  Coenzyme Q10 inhibits mitochondrial complex‐1 down‐regulation and nuclear factor‐kappa B activation , 2004, Journal of cellular and molecular medicine.

[264]  M. Beal,et al.  Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease , 2004, Experimental Neurology.

[265]  A. Reunanen,et al.  Prospective study of coffee consumption and risk of Parkinson's disease , 2008, European Journal of Clinical Nutrition.

[266]  S. Lorenzl,et al.  Minocycline enhances MPTP toxicity to dopaminergic neurons , 2003, Journal of neuroscience research.

[267]  F. Waldhauser,et al.  Circadian secretion pattern of melatonin in de novo Parkinsonian patients: evidence for phase-shifting properties of l-dopa , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[268]  F. Dajas,et al.  Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra 1 1 Published on the World Wide Web on 1 December 2000. , 2001, Brain Research.

[269]  A. Mayk,et al.  Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat , 1999, Journal of Neural Transmission.

[270]  C. Marsden,et al.  Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.

[271]  M. Hernán,et al.  Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease , 2006, Neurology.

[272]  A. Brand,et al.  Docosahexaenoic Acid Abundance in the Brain: A biodevice to Combat Oxidative Stress , 2002, Nutritional neuroscience.

[273]  Ninds Net-Pd Investigators.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[274]  Hee-Yong Kim.  Novel Metabolism of Docosahexaenoic Acid in Neural Cells* , 2007, Journal of Biological Chemistry.

[275]  Steven A. Smith,et al.  Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. , 2005, Journal of chemical neuroanatomy.

[276]  M. Youdim,et al.  Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline , 2004, Neuroscience Letters.

[277]  H. Tohgi,et al.  The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[278]  R. Tompkins.  Nonsteroidal anti-inflammatory drugs. , 2019, Minnesota medicine.

[279]  S. Yoon,et al.  The Cyclic AMP Response Element Directs Tyrosine Hydroxylase Expression in Catecholaminergic Central and Peripheral Nervous System Cell Lines from Transgenic Mice (*) , 1995, The Journal of Biological Chemistry.

[280]  H. Powers,et al.  Effects of riboflavin deficiency in rats on some aspects of iron metabolism. , 1983, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[281]  M. Reddy,et al.  Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. , 2008, Toxicology.

[282]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[283]  C. Marsden,et al.  Alpha-tocopherol levels in brain are not altered in Parkinson's disease. , 1992, Annals of neurology.

[284]  D. Prasad,et al.  Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: Complementary roles of L-type calcium channel and NMDA receptors , 2009, Neurobiology of Disease.

[285]  M. Beal,et al.  Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease , 2009, BMC Neuroscience.

[286]  T. Slater,et al.  Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour. , 1988, The Biochemical journal.

[287]  Marc W Fariss,et al.  Vitamin E therapy in Parkinson's disease. , 2003, Toxicology.

[288]  C. Shults.  Coenzyme Q10 in neurodegenerative diseases. , 2003, Current medicinal chemistry.

[289]  R. de Caterina,et al.  The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[290]  P. Whitton,et al.  Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection , 2010, British journal of pharmacology.

[291]  S. Hersch,et al.  Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice , 2003, Journal of neurochemistry.

[292]  R. Reiter,et al.  Melatonin is protective against MPTP-induced striatal and hippocampal lesions. , 1996, Life sciences.

[293]  S. Majumdar,et al.  Short-Term Risk for Stroke Is Doubled in Persons With Newly Treated Type 2 Diabetes Compared With Persons Without Diabetes: A Population-Based Cohort Study , 2007, Stroke.

[294]  J. Freudenheim,et al.  Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[295]  A. Merrill,et al.  Formation and mode of action of flavoproteins. , 1981, Annual review of nutrition.

[296]  N. Lunet,et al.  Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. , 2010, Journal of Alzheimer's disease : JAD.

[297]  M. Youdim,et al.  Regulation of protein kinase C by the anti‐Parkinson drug, MAO‐B inhibitor, rasagiline and its derivatives, in vivo , 2004, Journal of neurochemistry.

[298]  D. Surmeier,et al.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease , 2011, Neurobiology of Disease.

[299]  J. Lawler,et al.  Direct antioxidant properties of creatine. , 2002, Biochemical and biophysical research communications.

[300]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[301]  G. Logroscino,et al.  Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study , 2011, BMJ : British Medical Journal.

[302]  N. Greig,et al.  Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy , 2007, Experimental Neurology.

[303]  R. Prediger.  Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. , 2010, Journal of Alzheimer's disease : JAD.

[304]  C. Chow.  Vitamin E and oxidative stress. , 1991, Free radical biology & medicine.

[305]  M. Anagnostouli,et al.  Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism , 2003, Journal of the Neurological Sciences.

[306]  LeWitt Pa,et al.  Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. , 1994 .

[307]  G. Bertilsson,et al.  Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease , 2008, Journal of neuroscience research.

[308]  岩井 孝志.  Glucagon-like peptideの精神・神経障害に対する作用 , 2010 .

[309]  J. Pettegrew,et al.  Phosphocreatine-dependent Glutamate Uptake by Synaptic Vesicles , 1996, The Journal of Biological Chemistry.

[310]  W. Cass,et al.  Calcitriol Protection against Dopamine Loss Induced by Intracerebroventricular Administration of 6-Hydroxydopamine , 2006, Neurochemical Research.